Nantahala Capital Management LLC Purchases Shares of 810,074 USANA Health Sciences, Inc. $USNA

Nantahala Capital Management LLC acquired a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 810,074 shares of the company’s stock, valued at approximately $17,295,080.

Other large investors also recently modified their holdings of the company. Empowered Funds LLC acquired a new stake in shares of USANA Health Sciences during the 2nd quarter worth about $1,500,000. Public Employees Retirement System of Ohio acquired a new position in USANA Health Sciences in the 2nd quarter valued at about $384,000. Bank of America Corp DE acquired a new position in USANA Health Sciences in the 2nd quarter valued at about $968,000. Man Group plc acquired a new position in USANA Health Sciences in the 2nd quarter valued at about $490,000. Finally, Hsbc Holdings PLC bought a new position in USANA Health Sciences in the 2nd quarter valued at about $673,000. 54.25% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Finally, Zacks Research lowered USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, USANA Health Sciences presently has an average rating of “Sell”.

Insider Transactions at USANA Health Sciences

In other news, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director directly owned 4,230 shares in the company, valued at $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.82% of the company’s stock.

USANA Health Sciences Stock Performance

USNA opened at $14.06 on Friday. The stock has a fifty day moving average of $18.84 and a 200-day moving average of $18.81. The company has a market capitalization of $259.83 million, a P/E ratio of -11.62, a P/E/G ratio of 1.55 and a beta of 0.73. USANA Health Sciences, Inc. has a fifty-two week low of $12.57 and a fifty-two week high of $32.29.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The business had revenue of $223.27 million during the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, equities research analysts predict that USANA Health Sciences, Inc. will post 0.76 earnings per share for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.